NCT04825561View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-208

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

January 9, 2023

Study Completion Date

June 1, 2023

Conditions
Androgenetic Alopecia
Interventions
DRUG

AD-208

PO, Once daily(QD), 24weeks

DRUG

AD-2081

PO, Once daily(QD), 24weeks

DRUG

placebo of AD-208

PO, Once daily(QD), 24weeks

DRUG

placebo of AD-2081

PO, Once daily(QD), 24weeks

Trial Locations (1)

Unknown

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY